+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment for autonomic dysreflexia using trkA-IgG after spinal cord injury



Treatment for autonomic dysreflexia using trkA-IgG after spinal cord injury



Society for Neuroscience Abstracts 26(1-2): Abstract No -864 4



We have devised a strategy for treatment of autonomic dysreflexia (episodic hypertension) after spinal cord injury (SCI) using a fusion protein (trkA-IgG) containing the specific trkA receptor for nerve growth factor (NGF). We hypothesize that using trkA-IgG to sequester NGF in the injured spinal cord will prevent inappropriate growth of small-diameter primary afferent fibres in the dorsal horn of the spinal cord, therefore blocking the onset of autonomic dysreflexia after SCI. In vitro, trkA-IgG was produced using a baculovirus expression vector containing complementary DNA encoding the NGF binding domain of rat trkA fused to the Fc portion of human IgG. The trkA-IgG was secreted by spodoptera frugiperda (Sf9) insect cells infected with the baculovirus construct, then purified by affinity column and dialysis. Specific binding of the trkA-IgG to NGF was verified by dot blots and optical biosensor technology (Biacore): preliminary data indicate that after trkA-IgG immobilization onto a protein A chip, NGF bound to trkA-IgG at KD = 4.26x10-11M. Functional inhibition of NGF-induced neurite sprouting by trkA-IgG was confirmed using rat pheochromocytoma (PC12) cell culture assays. In vivo, the spinal cords of female Wistar rats were injured by 50 gram clip compression at the 4th thoracic level. Using an intrathecal catheter and Alzet osmotic pump, trkA-IgG (2.14mug/day) or non-immune control IgG (2.14mug/day) mixed with Pontamine sky blue dye was administered to the spinal cord caudal to the injury site. Penetration of the trkA-IgG and control IgG was confirmed by distribution of dye throughout the spinal cord. At 14 days post-injury, the effects of trkA-IgG versus control IgG on mean arterial pressure (MAP) and heart rate (HR) responses to colon distension and skin stimulation were compared. After infusion of control IgG, MAP typically increased by 40 mm Hg and HR decreased by 80 bpm following colon distension, with similar responses to stimulation of skin dermatomes near the lesion site. In contrast, small changes in MAP (uparw15 mm Hg) and HR (dwnarw10 bpm) were observed following trkA-IgG treatment. The degree of inflammation was also assessed using cresyl violet stain in transverse sections (30 mum) of the spinal cord at the 10th thoracic level. Neither the physical presence of the catheter, nor the trkA-IgG or control IgG, provoked an apparent inflammatory response in the spinal cord. These results indicate that treatment with trkA-IgG effectively reduces the magnitude of autonomic dysreflexia and causes no spinal cord inflammation after injury. Funding: Ontario Neurotrauma Foundation, Ontario Heart and Stroke Foundation.

(PDF emailed within 1 workday: $29.90)

Accession: 035980180

Download citation: RISBibTeXText


Related references

Incidence of autonomic dysreflexia and silent autonomic dysreflexia in men with spinal cord injury undergoing sperm retrieval: implications for clinical practice. Journal of Spinal Cord Medicine 31(1): 33-39, 2008

Autonomic dysreflexia in a tetraplegic patient due to a blocked urethral catheter: spinal cord injury patients with lesions above T-6 require prompt treatment of an obstructed urinary catheter to prevent life-threatening complications of autonomic dysreflexia. International Journal of Emergency Medicine 5(): 6-6, 2012

Neutralizing intraspinal nerve growth factor with a trkA-IgG fusion protein blocks the development of autonomic dysreflexia in a clip-compression model of spinal cord injury. Journal of Neurotrauma 19(12): 1531-1541, 2003

Mechanism and experimental treatment of autonomic dysreflexia after spinal cord injury. FASEB Journal 15(5): A1150, March 8, 2001

Intravesical capsaicin for treatment of autonomic dysreflexia in patients with spinal cord injury. Journal of Urology 155(5 SUPPL ): 591A, 1996

Latest approaches for the treatment of spasticity and autonomic dysreflexia in chronic spinal cord injury. Neurotherapeutics 8(2): 274-282, 2011

Reduction in Bladder-Related Autonomic Dysreflexia after OnabotulinumtoxinA Treatment in Spinal Cord Injury. Journal of Neurotrauma 33(18): 1651-1657, 2016

Acute management of autonomic dysreflexia: adults with spinal cord injury presenting to health-care facilities. Consortium for spinal cord. Journal of Spinal Cord Medicine 20(3): 284-308, 1997

Autonomic control of the heart and renal vascular bed during autonomic dysreflexia in high spinal cord injury. Clinical Autonomic Research 12(6): 457-464, 2003

Autonomic dysreflexia in spinal cord injury. Nursing Clinics of North America 9(4): 717-725, 1974

What causes autonomic dysreflexia after spinal cord injury?. Clinical Autonomic Research 12(6): 424-426, 2003

Autonomic dysreflexia/hyperreflexia in spinal cord injury. Auaa Journal 8(4): 12-12, 1988

Autonomic dysreflexia in pediatric spinal cord injury. Sci Nursing 19(2): 82-84, 2003

Autonomic dysreflexia in a parturient with spinal cord injury. Acta Anaesthesiologica Belgica 57(2): 161-162, 2006

Low spinal anesthesia for the prevention of autonomic dysreflexia in the spinal cord injury patient. Journal of Urology 122(3): 366-366, 1979